Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder

BACKGROUND: Oral pharmacological treatment for overactive bladder (OAB) consists of antimuscarinics and the beta-3 adrenergic agonist mirabegron. Antimuscarinic adverse events (AEs) such as dry mouth, constipation, and blurry vision can result in frequent treatment discontinuation rates, leaving par...

Descripción completa

Detalles Bibliográficos
Autores principales: Perk, Sinem, Wielage, Ronald C., Campbell, Noll L., Klein, Timothy M., Perkins, Anthony, Posta, Linda M., Yuran, Thomas, Klein, Robert W., Ng, Daniel B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397927/
https://www.ncbi.nlm.nih.gov/pubmed/27579830
http://dx.doi.org/10.18553/jmcp.2016.22.9.1072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397927/
https://www.ncbi.nlm.nih.gov/pubmed/27579830
http://dx.doi.org/10.18553/jmcp.2016.22.9.1072

Ejemplares similares